Actionable news
All posts from Actionable news
Actionable news in KERX: Keryx Biopharmaceuticals, Inc.,

FBR Weighs in on Keryx Biopharmaceuticals (KERX) as FDA Approves Second CMO for Auryxia

FBR Capital analyst Christopher James weighed in with a few insights on Keryx Biopharmaceuticals (NASDAQ:KERX), after the drug maker announced that the FDA granted approval for the second Auryxia contract manufacturer ahead of the November 13 PDUFA date. Shares of Keryx are currently trading at $6.24, up $0.62 or 11.03%.

James commented, “Keryx has been manufacturing Auryxia at the second CMO at risk, pending the regulatory approval. Although we are pleased to hear that the supply will be restored in the near future, we remain focused on Keryx’s strategy to...